FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today the United States Patent Office has allowed the Company's U.S. patent application No. 11/159,533 titled “Platelet-Derived Growth Factor Compositions and Methods of Use Thereof.” The allowed claims within this patent application cover compositions of platelet derived growth factor (PDGF) combined with matrix materials having defined characteristics, which cover the Company’s novel recombinant protein-device combination product candidates, including Augment™ Bone Graft and Augment™ Injectable Bone Graft. The new patent will remain in force until 2024, during which time it will prohibit the marketing of similar or generic versions of Augment, Augment Injectable, GEM 21S and potentially other products the Company has in development.
